Navigation Links
Tobira's Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV

SAN FRANCISCO, Feb. 17 /PRNewswire/ -- The first-ever-reported Phase II data for TBR-652, which is being developed by Tobira Therapeutics for the treatment of HIV infection, demonstrate that the CCR5 receptor antagonist provides potent antiviral activity and is generally safe and well-tolerated in its proof of concept trial. The data were released here today in an oral presentation at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).

In a Phase IIa trial involving 54 treatment-experienced HIV infected patients, a 10-day course of once-daily, TBR-652 monotherapy produced a median nadir decline from baseline in HIV viral load of up to 1.8 log10 copies/mL. There were no serious adverse events, deaths or study drug-related discontinuations in the study.  Dose dependent changes in MCP-1 concentrations were also observed, demonstrating TBR-652's dual CCR5/CCR2 mechanism of action and potential anti-inflammatory benefits.  

"These data demonstrate that TBR-652 offers potent viral suppression and excellent safety and tolerability in this short-term study," observed Calvin J. Cohen, M.D., M.Sc., of the Community Research Initiative of New England. "This compound provides the potential for once-daily dosing, without the need for a pharmacologic boosting agent, an important benefit for simplified dosing and ease of administration in early stage disease."

Dr. Cohen presented data from Study 652-2-201, a double-blind, placebo-controlled, dose-escalation trial in which patients were randomized four-to-one to receive doses of TBR-652 of 25mg, 50mg, 75mg, 100mg, 150mg and placebo.  

All patients were HIV treatment-experienced, though none had previously been treated with a CCR5 antagonist. Most adverse events in the study were mild in severity (Grade 1). There were no clinically significant trends in adverse events, laboratory tests, vital signs, or electrocardiogram measurements. Additionally, there were no liver function test elevations greater than Grade 1.

The antiviral activity of TBR-652, as evidenced by reductions in HIV viral load, is outlined in the following dose-escalation chart:

                     Median change from        
                    baseline after 10 days  Median nadir change from   
    Dosing cohort    (log10 copies/mL)      baseline (log10 copies/ mL)
    -------------  ----------------------   --------------------------
    25 mg                  -0.5                     -0.7
    -----                  ----                     ----
    50 mg                  -1.3                     -1.7
    -----                  ----                     ----
    75 mg                  -1.6                     -1.8
    -----                  ----                     ----
    100 mg                 -1.2                     -1.4
    ------                 ----                     ----
    150 mg                 -1.5                     -1.7
    ------                 ----                     ----
    placebo                +0.1                     -0.2
    -------                ----                     ----

Dr. Cohen noted that all patients in the 75-mg dosing group achieved a decline in HIV-1 RNA of at least 1.0 log10 copies/mL.  

"Today's data presentation represents an exciting milestone for Tobira," said James Sapirstein, President and CEO of Tobira Therapeutics. "TBR-652's unique properties, including once-daily dosing that may facilitate co-formulation with other antiretrovirals, such as nucleoside-sparing or ritonavir-sparing combinations, distinguish it from the early CCR5 antagonists.  Further, TBR-652's added CCR2 antagonism and potential anti-inflammatory benefits suggests a bright future for this high-potential compound."

About Tobira Therapeutics, Inc.

Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease.  The company was founded in 2006 by Eckard Weber, MD, a partner at Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development.

SOURCE Tobira Therapeutics, Inc.



SOURCE Tobira Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Oclaro Next-Generation Orion Fiber-Coupled Diode Laser Raises the Bar for Performance, Cost and Reliability for Solid State Lasers
2. WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
3. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
4. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
5. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
6. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
9. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
10. ISTA Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Once-Daily XiDay(TM)
11. Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Centers’ National Poison Data System (NPDS) reveals that in 2014, someone called a ... cases, over two million of which were human exposure cases. , The American ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. ... partner for the Nutraceutical Specialties products into oral solid dosage in the over ... , “We are pleased to announce our expanded distribution agreement with ASI.” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair ... polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support and ...
Breaking Medicine News(10 mins):